



## Correction to: *SLC12A2* variants cause a neurodevelopmental disorder or cochleovestibular defect

Alisdair McNeill, Emanuela Iovino, Luke Mansard, Christel Vache, David Baux, Emma Bedoukian, Helen Cox, John Dean, David Goudie, Ajith Kumar, Ruth Newbury-Ecob, Chiara Fallerini, Alessandra Renieri, Diego Lopercolo, Francesca Mari, Catherine Blanchet, Marjolaine Willems, Anne-Francoise Roux, Tommaso Pippucci, Eric Delpire. *SLC12A2* variants cause a neurodevelopmental disorder or cochleovestibular defect. *Brain*. 2020;143(8):2380–2387. <https://doi.org/10.1093/brain/awaa176>

The authors apologize for an error in the Funding section, which should read:

### Funding

Funding for the project was provided by the Wellcome Trust. We declare that those who collected data and deposited it in the DECIPHER database bear no responsibility for its use and interpretation in the current work. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003), a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute (grant number WT098051). Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. E.D. is funded by National Institutes of Health grants GM118944, DK093501 and R01DK110375. This research has been supported (not financially) by European Reference Network for rare malformation syndromes and rare intellectual and neurodevelopmental disorders, ERN-ITHACA (EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516). This ERN is partly co-funded by the European Union within the framework of the Third Health Programme 'ERN-2016 - Framework Partnership Agreement 2017-2021'.

These details have been corrected in this correction notice to preserve the published version of record.